Research group looking to bring Cuba's lung cancer vaccine to the United States
the ONA take:
As relations between the United States and Cuba normalize, groundbreaking lung cancer research and a vaccine may be early imports from the island nation.
A group that included from Roswell Park Cancer Institute’s (RPCI) president and CEO and New York Governor Andrew Cuomo met in face-to-face meetings with representatives and researchers from Cuba’s Center for Molecular Immunology (CIM) in which they finalized an agreement to bring CimaVax, the CIM’s lung cancer vaccine, to the United States.
CimaVax targets a growth factor (EGF) necessary for lung cancer to survive. By depleting the growth factor, the vaccine starves the cancer and slows its progression, prolonging patients’ lives.
Expansive clinical trials with published data show the vaccine effectively prolonged life, especially among patients younger than 60 years, compared with standard care, with minimal vaccine-related toxicity. The vaccine is administered as an injection in the shoulder once per month.
RPCI is preparing the paperwork for the FDA, and is hoping the FDA can begin its inspection within the next 2 to 3 months.
In addition, extensive safety data is currently available and may enable investigators to skip straight to a phase II study in patients. The researchers estimate the clinical trials, FDA approval, and other regulatory requirements would take 5 years to complete.
CimaVax is the first of several other potential collaborations between RPCI and CIM. Additional collaborations include potential use of CimaVax on colon, head and neck, prostate, breast, and pancreatic cancers, and a second vaccine that targets blood cancers.
As relations between the United States and Cuba normalize, groundbreaking lung cancer research and a vaccine may be early imports.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|